Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of biopharmaceutical royalties, through a non-recourse royalty-backed note secured by a portion of future royalties from Ziihera or zanidatamab-hrii.
The funding is backed by 30% of worldwide tiered royalties owed to Zymeworks by Jazz Pharmaceuticals and BeOne Medicines.
Under the terms, repayment will be made from 30% of global royalties on Ziihera, equating to a low- to mid-single digit upward tiering royalty.
Royalty Pharma will receive cumulative payments of 1.65 times the note amount by December 31, 2033, or 1.925 times the note amount at any time thereafter, after which no further payments will be due.
Royalty payments to Royalty Pharma will cease once the repayment cap is reached.
Zymeworks will retain 70% of royalties during the repayment period, with full royalty rights reverting after the note is satisfied.
Regulatory and commercial milestone payments under agreements with Jazz and BeOne, including up to $1.5 billion in potential remaining milestone payments, will be fully retained by Zymeworks.
In the pre-market trading, Royalty Pharma is 1.75% lesser at $45.40 on the Nasdaq.
On Friday, Zymeworks closed trading 2.18% lesser at $23.29 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.